Plasminogen activator inhibitor type 1, (PAI-1) the primary inhibitor of the tissuetype (tPA) and urokinase-type (uPA) plasminogen activators, has been implicated in a wide range of pathological processes, making it an attractive target for pharmacologic inhibition. Currently available small-molecule inhibitors of PAI-1 bind with relatively low affinity and do not inactivate PAI-1 in the presence of its cofactor, vitronectin. To search for novel PAI-1 inhibitors with improved potencies and new mechanisms of action, we screened a library selected to provide a range of biological activities and structural diversity. Five potential PAI-1 inhibitors were identified, and all were polyphenolic compounds including two related, naturally-occurring plant polyphenols that were structurally similar to compounds previously shown to provide cardiovascular benefit in vivo. Unique second generation compounds were synthesized and characterized, and several showed IC 50 values for PAI-1 between 10-200 nM. This represents an enhanced potency of 10-1000-fold over previously reported PAI-1 inactivators. Inhibition of PAI-1 by these compounds was reversible, and their primary mechanism of action was to block the initial association of PAI-1 with a protease. Consistent with this mechanism and in contrast to previously described PAI-1 inactivators, these compounds inactivate PAI-1 in the presence of vitronectin. Two of the compounds showed efficacy in ex vivo plasma and one blocked PAI-1 activity in vivo in mice. These data describe a novel family of high-affinity PAI-1-inactivating compounds with improved characteristics and in vivo efficacy, and suggest that the known cardiovascular benefits of dietary polyphenols may derive in part from their inactivation of PAI-1.
Plasminogen activator inhibitor type 1, (PAI-1) the primary inhibitor of the tissuetype (tPA) and urokinase-type (uPA) plasminogen activators, has been implicated in a wide range of pathological processes, making it an attractive target for pharmacologic inhibition. Currently available small-molecule inhibitors of PAI-1 bind with relatively low affinity and do not inactivate PAI-1 in the presence of its cofactor, vitronectin. To search for novel PAI-1 inhibitors with improved potencies and new mechanisms of action, we screened a library selected to provide a range of biological activities and structural diversity. Five potential PAI-1 inhibitors were identified, and all were polyphenolic compounds including two related, naturally-occurring plant polyphenols that were structurally similar to compounds previously shown to provide cardiovascular benefit in vivo. Unique second generation compounds were synthesized and characterized, and several showed IC 50 values for PAI-1 between 10-200 nM. This represents an enhanced potency of 10-1000-fold over previously reported PAI-1 inactivators. Inhibition of PAI-1 by these compounds was reversible, and their primary mechanism of action was to block the initial association of PAI-1 with a protease. Consistent with this mechanism and in contrast to previously described PAI-1 inactivators, these compounds inactivate PAI-1 in the presence of vitronectin. Two of the compounds showed efficacy in ex vivo plasma and one blocked PAI-1 activity in vivo in mice. These data describe a novel family of high-affinity PAI-1-inactivating compounds with improved characteristics and in vivo efficacy, and suggest that the known cardiovascular benefits of dietary polyphenols may derive in part from their inactivation of PAI-1.
PAI-1 is the primary physiologic inhibitor of uPA and tPA with a well characterized role in fibrinolysis (1) . PAI-1 also plays a role in many physiologic processes, including angiogenesis, wound healing, and cell migration (2) (3) (4) (5) (6) , and has been implicated in fibrotic diseases of the kidney and lung, and in tumor metastasis (7) (8) (9) (10) (11) . More recently, PAI-1 has been linked to obesity and metabolic syndrome (12) (13) (14) (15) (16) , and to the development of vascular diseases such as venous thrombosis and atherosclerosis (17) (18) (19) . The prospect that PAI-1 may play a direct role in the early development of a variety of diseases has made it an attractive target for drug development (20, 21) .
However, PAI-1's structural complexity has made the identification and development of PAI-1 inhibitors challenging. This is due in part to PAI-1's metastable structure, which can adopt several different conformations, including active, latent, cleaved, and protease complexed (1) . These different forms of PAI-1 provide conformational control of PAI-1 interactions and dictate its localization to either matrix or the cell surface and control its activity in cell signaling events (22, 23) .
Active PAI-1 inhibits protease targets and is associated with vitronectin in plasma or the extracellular matrix. In contrast, PAI-1-protease complexes shift affinity from vitronectin to receptors of the low density lipoprotein receptor (LDL) family, transferring PAI-1 from vitronectin to the cell surface (22) . Active PAI-1 is inherently unstable and it undergoes a spontaneous conformational change that results in inactivation of PAI-1 to a latent form that does not bind either vitronectin or LDL-receptor family members with high affinity (22, 24) . The flexible structure of PAI-1, the lack of a rigid active site, and its multiple functions all contribute to the difficulties in identifying and designing small-molecule PAI-1 inactivators. Despite these obstacles, several smallmolecule PAI-1 inhibitors have been described (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) ; however, each has significant limitations that have reduced their potential for further drug development.
One of the best characterized compounds is PAI-039, also known as tiplaxtinin, which has been shown to reduce physiologic PAI-1 activity and to be efficacious in animal models of disease (3, (37) (38) (39) . However, PAI-039 has relatively low affinity for PAI-1, and does not inhibit vitronectin-bound PAI-1 (32, 40) . In order to develop better PAI-1 inactivators, we have screened a library of known compounds for high affinity PAI-1 inhibitors with improved solubility and activity against vitronectin-bound PAI-1. A high-throughput screen of the MicroSource SPECTRUM library identified five novel PAI-1 inactivating compounds. Two of the molecules identified were related natural polyphenolic compounds, which suggested a potential structure-activity relationship (SAR). Second generation compounds were designed and synthesized to probe this SAR and were tested for their ability to block PAI-1 activity in both purified systems and in vivo.
Experimental Procedures
Primary Screen-In conjunction with the Center for Chemical Genomics (CCG) at the University of Michigan, we developed a PAI-1 activity assay to screen for compounds with anti-PAI-1 activity in the MicroSource SPECTRUM compound collection. This collection consists of known drugs, compounds approved for agricultural use, natural products, and other bioactive compounds. A chromogenic assay was used with a 2:1 molar ratio of PAI-1 to uPA. We selected uPA because it is considerably more active toward low molecular weight substrates than is tPA, allowing for more than 10-fold lower concentrations of uPA and PAI-1 in this screen (5 nM uPA and 10 nM PAI-1) compared to assays using tPA (70 nM tPA and 140 nM PAI-1) (41). The screen was performed in 384-well microtiter plates in the CCG lab as follows: recombinant active human PAI-1 (final 10 nM) was incubated for 60 min at 23°C either with or without 10 μM of each compound in HTS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% Tween-20), uPA was added (final 5 nM) to each reaction well, and incubation continued for an additional 30 min at 23°C. Residual uPA activity in each reaction mixture was then determined with pGlu-Gly-Arg p-nitroanilide chromogenic substrate (Sigma) (final 0.25 mM) measured spectrophotometrically at 405 nm after 60 min. Compounds that inactivated PAI-1 were identified by the restoration of uPA activity. The extent of uPA activity restoration was determined by comparing each drug-containing sample to wells with untreated PAI-1 (100% PAI-1 activity) and to wells with uPA only (0% PAI-1 activity). The data from this screen were then uploaded to the CCG informatics system and positive hits were identified as any compound that increased uPA activity by more than 3 standard deviations above control and compound wells on each plate. Using these selection criteria, the primary screen of 2000 compounds yielded an initial total of 23 compounds deemed positive hits. Each of these hits was then re-assayed by dose response testing using the same chromogenic assay with the compounds at the following concentrations (0.1, 0.32, 1, 3.2, 10, 32, and 100 μM) in duplicate by the CCG. In this secondary analysis 19 of the 23 compounds were deemed positive; however, 3 of these compounds were known to have significant toxicity and therefore were not analyzed further. Samples of the 16 remaining compounds were then obtained from the CCG for further analysis in our laboratory. These more detailed analyses first investigated whether each compound had intrinsic absorbance at 405 nm that would give false positive absorbance readings, or was not completely soluble in the assay buffer system used since insolubility and compound precipitation could likewise lead to false positive absorbance readings. Each compound was also tested for its ability to directly block PAI-1 complex formation with uPA by SDS-PAGE analysis. For this latter analysis each compound was incubated at 10 µM with 1 µg of PAI-1 for 15 min at 23°C followed by the addition of 1 µg of uPA for an additional 5 min at 37°C. Approximately half of the 16 compounds either had intrinsic absorbance at 405 nm or insolubility in the buffer system. Of the remaining compounds, 5 directly inhibited PAI-1 activity. Enzymatic AssaysRecombinant nonglycosylated or glycosylated active human PAI-1 (PAI-1 and PAI-1 glyco , respectively) or recombinant murine PAI-1 (mPAI-1) was incubated at 2 nM for 15 min at 23°C with increasing concentrations of each compound in assay buffer (40 mM HEPES, pH 7.8, 100 mM NaCl, 0.005% Tween-20, 0.1% DMSO), followed by the addition of uPA (Molecular Innovations) or tPA (Genentech) to 3 nM and further incubation for 30 min at 23°C. At each drug concentration, parallel control reactions without PAI-1 were assembled. Residual enzymatic activity was determined by addition of an equal volume of 100 μM Z-Gly-GlyArg-AMC (Calbiochem) fluorogenic substrate for uPA or Pefafluor tPA (Centerchem) for tPA, and the rate of AMC release monitored at 23°C (Ex 370 nm and Em 440 nm). The percent change in PAI-1 activity was determined according to equation 1,
where E i is the enzyme activity at drug concentration i; P i is the enzyme activity in the presence of PAI-1 at drug concentration i; E 0 is the enzyme activity in the absence of drug; and P 0 is the enzyme activity in the presence of PAI-1 in the absence of drug. The effect of the compounds on 2 nM anti-thrombin III (ATIII) in the presence of 3 U/ml heparin was also determined using 3 nM α-thrombin. The reactions were assembled as above except that 10% DMSO was included in the assay buffer to ensure compound solubility at the higher concentrations used. Residual α-thrombin activity was measured using an equal volume of 100 μM benzoyl-Phe-Val-Arg-AMC (Calbiochem). Binding of PAI-1 to anhydrotrypsin was then monitored at 25°C at a flow rate of 30 µl/min for 2.5 min, followed by 2 min of dissociation. Chip surfaces were regenerated with a 1 min pulse of 10 mM glycine, pH 1.5, followed by a 1 min wash of assay buffer. Injections were performed using Wizard Customized Application program in automated mode. Binding experiments were performed in duplicate and were corrected for background and bulk refractive index by subtraction of the reference flow cell, and data analyzed with BIAevaluation 3.1 (Biacore) by linear fitting of the initial association phase. Compoundinduced alterations in PAI-1 binding to anhydrotrypsin were determined by comparing the initial slopes of the association phases since there is a linear relationship between the slope and the concentration of available active PAI-1 (Supplemental figure S1 and (32)). These data were then fit to an exponential association equation to determine the apparent affinity between PAI-1 and compound.
Synthesis of New Inhibitors-
To monitor the inhibition of vitronectinbound PAI-1, human vitronectin purified under non-denaturing conditions was coupled to a CM5 sensor chip to a surface density of ~1000 RU (32) . Five nM PAI-1 was injected over the chip at a rate of 20 μl/min at 25°C for 4 min, followed by assay buffer alone or 100 nM CDE-066 in assay buffer for 10 min, and then 100 nM uPA for 5 min. After injections of PAI-1 or CDE-066, the chip was washed with assay buffer for approximately 4 min. Results were corrected for background and bulk refractive index in BIAevaluation 3.1.
SDS-PAGE/Western
Blotting-Human PAI-1 at 2 nM was incubated with the indicated concentration of the compound for 15 min at 23°C in assay buffer, followed by a 30 min incubation with 3 nM uPA or tPA. Samples were analyzed via reducing SDS-PAGE with 10% Tris-HCl gels (Bio-Rad) and transferred onto PVDF overnight. PAI-1 was detected using polyclonal high-titer sheep anti-human PAI-1 antibody (Molecular Innovations), HRP-conjugated donkey anti-sheep IgG (Jackson ImmunoResearch Laboratories), and Pierce ECL Western Blotting Substrate (Thermo Scientific). Reversibility assay-The reversibility of PAI-1 inactivation by the compounds was performed as essentially as described (32) . PAI-1 (2 nM) was incubated with each compound at 3-to 5-fold its IC 50 value as determined using uPA, followed by serial 2-fold dilutions into assay buffer and further incubation to allow dissociation of the compounds from PAI-1. UPA (3.5 nM) was then added and PAI-1 activity was determined. The PAI-1 activity in compound-containing samples recovered at each dilution was calculated as a percentage of the activity in PAI-1 dilutions carried out in parallel without compound. Initial concentrations of compounds were 150 nM CDE-008, 75 nM CDE-031, 400 nM CDE-034, 300 nM CDE-056, 50 nM CDE-066, and 50 nM CDE-082. Inhibition of mPAI-1 in ex vivo plasmaMurine PAI-1 was added to PAI-1-depleted murine plasma (Molecular Innovations) at 5000 pg/ml. Ten microliters of increasing concentrations of compound in assay buffer containing 10% DMSO and 10 μl of mPAI-1-reconstituted plasma were incubated for 15 min at 23°C in a filter plate (Millipore), followed by the addition of 25 μl of SeroMAP beads (Luminex) coupled to uPA (2500 beads/well), and further incubated in the dark on a microtiter plate shaker for 2 h. The plate was vacuum washed 3X with wash buffer (PBS, pH 7.4, 0.05% Tween-20), then 50 µl of PBS, pH 7.4, 1% BSA and 50 µl of 4 µg/ml biotin-labeled rabbit anti-mPAI-1 (Molecular Innovations) was added to each well and the plate incubated at 23°C in the dark on a microtiter plate shaker for 1 h. After vacuum washing 3X, 50 µl of PBS, pH 7.4, 1% BSA and 50 µl of 4 µg/ml streptavidin-Rphycoerythrin conjugate (Molecular Probes) was added to each well and incubated shaking at 23°C for 30 min in the dark. After another 3X wash, 100 µl of sheath fluid (Luminex) was added to each well, shaken for 5 min in the dark at 23°C and read on a Luminex 100 (Median setting, 50 µl sample size, 100 events/bead). Mean Fluorescence Intensities of unknown samples were converted to pg/ml base on a standard curve of mPAI-1 in mPAI-1-depleted plasma using a five-parameter regression formula (Masterplex QT v4.0, Miraibio). Plasma enzymatic assay-Citrated blood was collected from the inferior vena cava (IVC) of C57Bl6J mice that were either PAI-1 null or vitronectin/PAI-1 null and plasma prepared by centrifugation (15 min at 1500×g). The plasma was treated with 10 µg/ml Aprotinin (Roche) for 15 min at 23°C before reconstituting with 20 nM PAI-1. Plasma (10 µl, with or without PAI-1) was placed in microtiter wells with 80 µl of CDE-066 or PAI-039, synthesized as described (40) , in assay buffer containing 10% DMSO and incubated for 15 min at 23°C, followed by addition of 10 µl 25 nM uPA and further incubation for 30 min. Residual enzymatic activity was monitored as above using the fluorogenic uPA substrate, and PAI-1 activity was determined using eq. 1. Transgenic mice  heterozygous for murine PAI-1 overexpression (10) were weighed then anesthetized with isoflurane for the duration of the experiment. The IVC was isolated and 50 µl of citrated blood was collected as pretreatment samples. The syringe was replaced with a syringe containing vehicle or CDE-066 (in lactated Ringers) and 100 µl was injected for doses of 3, 10, and 30 mg/kg. After 1 h, 300 µl of citrated blood was collected via IVC, after which mice were euthanized.
Inhibition of PAI-1 in vivo-
Plasma was isolated by centrifugation at 1500×g for 15 min at 23°C. All animal experiments were approved by the Institutional Animal Care and Use Committee of Unit for Laboratory Animal Medicine at University of Michigan. To determine active murine PAI-1 levels in the plasma, 10 µl of plasma, diluted in PAI-1-depleted murine plasma (Molecular Innovations), 10 µl buffer (PBS, pH 7.4, 1% BSA) and 25 µl of uPAcoupled SeroMAP beads were added to a filter plate and incubated shaking overnight at 4 o C in the dark, and the reactions analyzed as above in the ex vivo plasma assay. Data and Statistical Analysis-Data were analyzed and IC 50 values calculated using Grafit 5. Apparent K D values for the binding of compounds to PAI-1 were determined using GraphPad Prism 4. Data were analyzed for significance with a student's t-test using non-diluted samples in the reversibility assays and the 0 mg/kg CDE-066 treatment in the in vivo assays as the control groups, with p < 0.05 considered significant.
RESULTS

High
Throughput Screen. The MicroSource SPECTRUM compound library was screened under stringent conditions such that PAI-1 was present at a 2-fold molar excess over uPA, and each compound was tested at a concentration of 10 µM. The statistical criteria of 3 standard deviations above the control and compound means on each plate resulted in 23 hits. These compounds were further tested by dose response analysis, and 19 remained positive in this secondary screen. Of these, 16 were deemed safe and subjected to further study including SDS-PAGE analysis of complex formation between PAI-1 and uPA. Based on these analyses, 5 compounds were confirmed as PAI-1 inhibitors in both enzymatic and SDS-PAGE assays, yielding a final hit rate of 0.25%. The structures and IC 50 s of these 5 compounds along with two related compounds are shown in Figure 1 .
Each of these five compounds contain polyphenolic moieties, and three of them, tannic acid (TA), epigallocatechin-3,5-digallate (EGCDG), and sennoside A, are naturally occurring plant polyphenols with reported biological activities (42) (43) (44) (45) (46) . The former two compounds, TA and EGCDG, have highly related structures that both contain galloyl or gallo-galloyl moieties suggesting the possibility of an SAR between polyphenols in general, and more specifically gallic acid moieties, and PAI-1 inactivation. We therefore examined two additional galloylcontaining compounds, epigallocatechin monogallate (EGCG) and gallic acid (Figure 1 B & F). Monomeric gallic acid was 1000-fold less active toward PAI-1 than TA, whereas EGCG inhibited PAI-1 only approximately 10-fold less well than TA. Thus, each of the galloyl-containing compounds was able to inhibit PAI-1, but the efficacy of inhibition appears dependent on the number of galloyl units in each compound and their relative orientation or context.
Synthetic Compounds. The IC 50 value obtained with TA of 7 nM was approximately 1000-fold lower than our previously reported IC 50 value for the PAI-1 inactivator, PAI-039 (32), and is markedly lower than any previously reported small-molecule PAI-1 inactivating compound (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Likewise the IC 50 s obtained with EGCG and EGCDG were also significantly better than PAI-039 and most other PAI-1 inactivators, suggesting that galloyl-containing compounds may represent a potent new family of PAI-1 inactivating compounds. However, TA is not an ideal drug candidate as its molecular weight of nearly 2000 Daltons is considered too large, and it was subject to aggregation at micromolar concentrations. Therefore, we synthesized a series of novel compounds containing different numbers of galloyl moieties in different structural configurations and compared their activity against PAI-1 to determine a potential SAR between galloylcontaining compounds and PAI-1 inhibition. In addition, to make this analysis sensitive to inactivators with low nanomolar IC 50 s, the PAI-1 concentration in the assay was lowered from 10 nM to 2 nM. Using these optimized assay conditions, we were able to accurately determine IC 50 s for several novel compounds. Six of these compounds, four digallates, one trigallate, and one pentagallate, are shown in Table I ). The activity of each compound against glycosylated human PAI-1 (PAI-1 glyco ) and murine PAI-1 (mPAI-1) was also compared to nonglycosylated recombinant human PAI-1 (PAI-1) (Table I) . In general the compounds inhibited PAI-1 glyco as well as the nonglycosylated form; however, most inhibited mPAI-1 less well than human PAI-1. The two exceptions were the pentagallate, CDE-066, and TA, which inhibited all forms of PAI-1 equally well.
The inactivation of PAI-1 by the polyphenolic compounds was specific, since only TA and CDE-082 (IC 50 >10 µM) showed any inhibition of the related serpin ATIII. Some of the gallate-containing compounds tested did show an apparent inhibition of tPA in assays with a chromogenic or fluorogenic substrate; however, little inhibition of tPA by these compounds was seen when tPA's physiologic substrate, plasminogen, was used (Supplementary figure S2) , suggesting that the compounds may be interacting with the low molecular weight tPA substrates.
It is also apparent from these data that while a single gallate (gallic acid, 6.6 µM) is a relatively poor inhibitor of PAI-1, a minimum of two galloyl units translates into significant anti-PAI-1 activity (20-116 nM, Figure 2 & Table I ). Compound CDE-008 was compared to several similar digallates with linkers of different lengths between the gallate moieties, and CDE-008 was found to have the optimal distance between the galloyl units (data not shown). To further explore structural requirements for digalloyl compound inhibition of PAI-1, we examined 1,2-disubstituted galloyl units on different ring structures to determine whether cis (CDE-031), trans (CDE-034), or planar (CDE-056) relationships between galloyl units inhibited PAI-1 more effectively. All of these compounds were active against PAI-1 with the cis form (CDE-031) being approximately 2-fold more active against PAI-1 than the acyclic CDE-008. These data demonstrate that the relative orientation of the gallates is important for anti-PAI-1 activity, with the cis form inhibiting PAI-1 approximately 4-fold better than the planar form and approximately 6-fold better than the trans form (Table I) .
SPR Analysis. To establish binding constants for the drugs to PAI-1, an indirect approach using SPR was employed. Varying concentrations of each drug were preincubated with PAI-1 in solution and then passed over immobilized anhydrotrypsin, and the loss of PAI-1 binding to anhydrotrypsin was quantified. We have previously shown for PAI-1 binding to vitronectin (32) , that the slope of the association phase of PAI-1 binding to an immobilized ligand has a linear relationship with the concentration of available active PAI-1 in solution. This relationship is also true for PAI-1 binding to immobilized anhydrotrypsin (Supplementary figure S1) . Thus, when the slopes of the association phase are plotted as a percent of control PAI-1 binding in the absence of compound versus the concentration of the compound, an IC 50 can be calculated for the drug-induced inhibition of PAI-1 interaction with anhydrotrypsin ( Figure 3) . From a transformation of these data, the apparent K D s for all seven compounds binding to PAI-1 can be calculated (Table II) . The apparent K D s range from 3.1 nM to 67 nM and are significantly tighter than previously reported values for other PAI-1 inactivators (28, 32, 33, 40) . These values are also similar to the IC 50 s calculated in PAI-1 inhibition assays (Table I ). These data indicate that drug binding interferes with the initial association of PAI-1 with the protease and can block formation of the PAI-1-protease Michaelislike complex.
SDS-PAGE. Each compound was also tested for its ability to block complex formation between PAI-1 and PAs, and examples of CDE-008, CDE-066 and CDE-082 are shown in Figure 4 . For these studies each compound was incubated with PAI-1, then either uPA or tPA was added and the formation of SDS-stable complexes was monitored by SDS-PAGE. The concentrations of PAI-1 and PAs were the same as those used in the enzyme assays ( Figure 1 & Table I ), and we observed comparable IC 50 s between the two techniques. Inhibition of covalent complex formation also closely mirrored inhibition of PAI-1 binding to anhydrotrypsin ( Figure 3 & Table II ). An increase in PAI-1 cleavage was also noted with each compound primarily at compound concentrations just below the IC 50 ; however, this was modest compared to the near complete loss of covalent complex, and much less cleavage was observed at compound concentrations above the IC 50 . Together with the SPR studies, these data suggest that the principal mechanism of PAI-1 inactivation by these compounds is the inhibition of PAI-1 Michaelis-like complex formation with PAs, but that at concentrations near the IC 50 some increase of PAI-1 substrate behavior may be induced.
Inactivation of PAI-1 is reversible. To test whether the inhibition of PAI-1 by the synthetic polyphenols was reversible, PAI-1 and each synthetic compound was incubated at a concentration where most of the antiproteolytic activity of PAI-1 was abolished. The mixtures were then serially diluted to reduce the compound concentrations, incubated for an additional 30 min, and the mixtures tested for restoration of PAI-1 activity. Figure 5 shows that for each synthetic polyphenol, PAI-1 activity increased upon dilution, indicating that PAI-1 inactivation by the compounds is reversible. The extent of PAI-1 activity recovered with each compound was slightly less than predicted, suggesting that the rate of dissociation between PAI-1 and these novel compounds is relatively slow and the samples may not have reached a new equilibrium after 30 min. Consistent with this mechanism, incubation of PAI-1 for various times with CDE-066, the most potent synthetic compound, demonstrated that the IC 50 remained unchanged from 15 min until termination of the experiment at 4 hours (Supplementary figure S3) . These data indicate that the compounds do not irreversibly modify PAI-1, and are consistent with a high affinity reversible mechanism of action.
Inhibition of mPAI-1 in plasma.
Each of the new compounds was tested for anti-PAI-1 activity in ex vivo plasma. This tests the ability of the drugs to inhibit mPAI-1 in the presence of plasma proteins, including vitronectin. None of the newly generated digallate compounds were active against mPAI-1 in the plasma activity assay (Figure 6 ). This was likely due to high non-specific protein binding of these digallates in plasma since the digallates were also ineffective against mPAI-1 in buffers containing high concentrations of BSA (data not shown). In contrast, all of the compounds with at least 3 galloyl moieties inhibited mPAI-1 in the plasma, including the trigallate (CDE-082), the pentagallate (CDE-066), and TA. Overall, TA had the lowest IC 50 against mPAI-1 in plasma (data not shown) but it was less specific than the novel polyphenols as it also inhibited normal plasma clotting, whereas CDE-066 and CDE-082 did not (Supplementary figure S4) . CDE-066 exhibited the lowest IC 50 of the new compounds in plasma, and was also significantly more specific than TA, therefore CDE-066 was used in further studies in plasma and in vivo.
Our previous studies with PAI-039, the most widely studied PAI-1 small-molecule inhibitor, indicated that it is unable to inhibit PAI-1 bound to vitronectin (32) , and one of the main objectives of the current study was to identify compounds that could inhibit PAI-1 in the presence of vitronectin. This was examined by adding a known amount of PAI-1 to murine plasma from either PAI-1 null mice or from mice doubly null for PAI-1 and vitronectin. After incubating the PAI-1 in these plasmas, samples were incubated with dilutions of either CDE-066 or PAI-039 and then tested for PAI-1 inhibition of uPA. Figure 7 demonstrates that unlike PAI-039, which is only inhibitory in plasma that lacks vitronectin, CDE-066 inhibited PAI-1 equally well in plasma with or with out physiologic vitronectin.
The ability of CDE-066 to inactivate PAI-1 bound to purified vitronectin was verified in vitro via BIAcore. To be certain that the PAI-1 was in complex with vitronectin, PAI-1 was injected over immobilized vitronectin and complex formation was detected by changes in relative response units. These data demonstrate that as expected active PAI-1 binds vitronectin with high affinity and dissociates very slowly from immobilized vitronectin; however, upon reaction with uPA, PAI-1 affinity for vitronectin is reduced by several orders of magnitude (22, 24) and the PAI-1 rapidly dissociates from vitronectin, (Figure 8 , large dots), In contrast, PAI-1 bound to vitronectin and then exposed to 100 nM CDE-066 does not dissociate from the immobilized vitronectin following the uPA injection ( Figure 8, small dots) ., These data indicate that CDE-066 blocks the association of uPA with PAI-1 even when in complex with vitronectin, and are consistent with the hypothesis that the primary mechanism by which CDE-066 inactivates PAI-1 is to prevent non-covalent complex formation with target proteases. These data also demonstrate that CDE-066 is not inducing PAI-1 cleavage as a substrate, or latency since both cleaved and latent PAI-1 also exhibit low affinity for vitronectin (22, 24) , and would likewise result in loss of PAI-1 signal from the chip. Finally, consistent with the reversibility studies shown in Figure 5 , these data indicate that the dissociation of CDE-066 from PAI-1 is relatively slow since even after 240 seconds of wash PAI-1 is still inhibited by CDE-066.
PAI-1 inactivation in vivo. Finally, to examine whether CDE-066 inhibits murine PAI-1 in vivo, mice overexpressing PAI-1 were treated acutely with either vehicle or increasing concentrations of CDE-066. Plasma samples were removed from each mouse before treatment and then one hour following IV infusion of CDE-066 at the concentrations indicated ( Figure 9) . Plasma samples were then tested for active PAI-1 levels. While a small increase in active PAI-1 was observed in the vehicle-treated animals, a dose-dependent decrease in active PAI-1 was observed after 1 hour of treatment with CDE-066. These data indicate that CDE-066 can significantly inhibit PAI-1 in vivo.
DISCUSSION
PAI-1 is thought to play a role in several chronic "lifestyle" diseases, including cardiovascular (CVD) and fibrotic diseases, and metabolic syndrome. These pathologic associations make PAI-1 an ideal drug target; however, its metastable structure has made it a difficult candidate for drug design and study. To date most small-molecule inhibitors of PAI-1 lack high affinity for PAI-1 and are unable to inhibit PAI-1 in the presence of its plasma binding protein, vitronectin. To identify higher affinity inhibitors with better drug development potential, a high stringency screening assay was performed and a class of polyphenolic compounds was identified with anti-PAI-1 activity. A subset of these with the highest anti-PAI-1 activity contained galloyl moieties, and one, TA, demonstrated the lowest IC 50 of any small-molecule PAI-1 inhibitor yet reported. One other study has identified members of the acylphloroglucinol class of polyphenols, sideroxylonals A-C, as potential PAI-1 inactivating compounds (27) . However, the reported IC 50 s of these compounds (3.3-5.3 μM) are 2-3 orders of magnitude higher than TA and the novel synthetic polyphenols described here and are comparable to the IC 50 of the simplest gallate compound in the current study, gallic acid (6.6 μM). This suggests that many polyphenolic compounds may share PAI-1 inactivating activity, but that the galloyl moiety may be a critical determinant in polyphenols for potent anti-PAI-1 activity.
Despite the low IC 50 of TA and its ability to inhibit PAI-1 in the high protein environment of plasma (data not shown), it is not an ideal drug candidate due to its molecular weight of nearly 2000 Daltons and its relative promiscuity, interacting with other proteins as well as itself at low-to midmicromolar concentrations. Nonetheless, the inhibition of PAI-1 by TA and other gallatecontaining molecules (EGCG, EGCDG, and gallic acid), formed the basis for development of follow-up compounds with improved properties compared to these naturally occurring polyphenols. Smaller di-, tri-, and pentagallates were designed with improved solubility in physiologic buffers and greater specificity toward PAI-1. These studies determined that while two galloyl moieties were sufficient to provide potent anti-PAI-1 activity, a minimum of 3 galloyl groups was required for efficacy in plasma. This suggests the relationship between specificity for PAI-1 and non-specific bulk protein binding is complex and is not dependent on only the number of galloyl subunits.
The synthetic polyphenolic derivatives demonstrate clear advantages over previous pharmacologic inactivators of PAI-1. For example most of the existing PAI-1 inhibitors exhibit IC 50 s in the low-to mid-micromolar range in comparable in vitro assays, which is several orders of magnitude less potent than the best novel synthetic polyphenolic derivatives described here (25) (26) (27) 29, 30, 32, (34) (35) (36) . Another class of PAI-1 inhibitors based on diketopiperazine derivatives have been described with in vitro IC 50 values reported in the 0.2-1 µM range; however, these compounds suffered from considerable physicochemical problems such as insolubility in physiologic buffer systems and were not subject to further development (47) . CDE-066, in contrast, is soluble in physiologic saline solution at concentrations greater than 10 mM without loss of anti-PAI-1 activity (data not shown). Two other PAI-1 inactivators have been described with IC 50 s reported in the midnanomolar range; however, these compounds are ineffective against vitronectin-bound PAI-1, the predominant form of PAI-1 in plasma and the extracellular matrix (28, 33) . Likewise several compounds with micromolar IC 50 s are also protected from inactivation when bound to vitronectin (26, 32) . The resistance of vitronectin-bound PAI-1 to these inhibitors is thought to be due to the location of the binding site for these compounds, in a hydrophobic cavity on PAI-1 that is defined by α-helices D and E and β-strands 1A and 2A, and that is directly adjacent to the vitronectin-binding site (26, 28, 32) . In contrast, the CDE-066 compound shows vitronectin-independent anti-PAI-1 activity in a purified system, in ex vivo plasma, and in vivo in PAI-1 transgenic mice.
The primary mechanism of action by which CDE-066 and the other the synthetic polyphenols inactivate PAI-1 appears to be by binding to PAI-1 in a reversible manner and preventing stabilization of the non-covalent Michaelis complex with target proteases. This is demonstrated in Figure 3 wherein preincubation of PAI-1 with each of the compounds inhibits its binding to the inactive protease, anhydrotrypsin. Identical data were also obtained in similar experiments using an inactive mutant of tPA (data not shown), indicating that the effect of the compounds on the initial association of PAI-1 with a protease is independent of the target protease. The SDS-PAGE analysis shown in Figure 4 suggests that the polyphenolic compounds can also promote substrate behavior in PAI-1. However, in contrast to the loss of Michaelis complex formation (Figure 3 ) and the loss of covalent complex formation ( Figure 4 ) the extent of cleavage observed is not dose dependent with the compounds added and varies with compound and target enzyme. It is possible that the extent of cleavage may be over-estimated in these experiments due to complex dissociation during SDS-PAGE. Note for example that even in the absence of any compound, cleaved PAI-1 is apparent under experimental conditions where the stoichiometry of inhibition is near 1 (SI = 1.06, data not shown). Finally, consistent with the primary mechanism of action being inhibition of PAI-1:protease association, SPR experiments demonstrated that no CDE-066-dependent PAI-1 cleavage was detected when PAI-1 bound to vitronectin was reacted with active uPA (Figure 8 ). This suggests that the combination of the compounds and denaturants during SDS-PAGE may alter how PAI-1 is observed to behave.
The identification of naturally-occurring polyphenols as a class of PAI-1 inhibitors is intriguing since such compounds, especially polyphenols derived from teas, fruits, and cocoa, have been suggested in recent years to provide benefit against pathologies such as chronic inflammation, neurodegeneration, cancer, and CVD (48) (49) (50) . Several mechanisms of action have been proposed for dietary polyphenols, characterizing these compounds as anti-oxidants, anti-platelet agents, and anti-inflammatory agents. Of particular relevance to PAI-1 are the proposed mechanisms by which dietary polyphenols may regulate hemostasis and prevent CVD. In ex vivo and cell culture studies, dietary polyphenols have been shown to reduce tissue factor expression (51), increase plasminogen activator levels (52) , and decrease PAI-1 via changes in gene expression (53) . These effects are observed at micromolar concentrations of the compounds, a dose range that is well within the effective concentrations of the polyphenols identified in our study. Thus, it is possible that a previously unrecognized direct inactivation of PAI-1 may contribute to the complex pro-fibrinolytic and cardioprotective effects associated with dietary polyphenols. Future studies will focus on improving the specificity and activity of this class of synthetic polyphenolic compounds against PAI-1 as well as clarifying the role that direct PAI-1 inactivation may play in the healthful benefits derived from dietary polyphenols. tannic acid; EGCDG, epigallocatechin-3,5-digallate; EGCG, epigallocatechin monogallate; CVD, cardiovascular disease; CCG, Center for Chemical Genomics. Figure 4 . CDE compounds inhibit complex formation between PAI-1 and uPA or tPA. PAI-1 (2 nM) was incubated with 10-fold dilutions of CDE-008 (A), -066 (B), and -082 (C) for 15 min at 23°C in assay buffer. Then uPA (left panels) or tPA (right panels) was added (3 nM final) and complexes were formed at 23°C for 30 min. Samples were analyzed by reducing SDS-PAGE followed by transfer to PVDF membranes and immunoblotting for PAI-1. SDS-stable complexes (asterisk), unreacted PAI-1 (open arrowhead) and cleaved PAI-1 (closed arrowhead) were detected. Figure 5 . Inactivation of PAI-1 by the synthetic inhibitors is reversible. PAI-1 (2 nM) was incubated with the compounds shown at 3-to 5-fold excess concentrations over the IC 50 of each compound for 15 min, then serially diluted 1:1 three times and further incubated for 30 min. PAI-1 activity was determined as described in the Experimental Procedures and is shown as a percentage of control activity without compound. The data represent the mean ±SEM of at least 3 independent experiments and were evaluated against the activities of the undiluted samples using a student's t-test (* p < 0.05, ** p < 0.01). The data represent the mean ±SEM, n = 5 at each dose, and were evaluated against the 0 mg/kg treatment using a student's t-test (* p < 0.05, ** p < 0.01). Figure 1 by guest on June 29, 2017 
